EP 4252774 A1 20231004 - COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER
Title (en)
COMBINATION THERAPY FOR TREATING PIK3CA-MUTATED CANCER
Title (de)
KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON PIK3CA-MUTIERTEM KREBS
Title (fr)
POLYTHÉRAPIE POUR TRAITER UN CANCER À MUTATION PIK3CA
Publication
Application
Priority
- CN 202011379205 A 20201130
- CN 2021134189 W 20211130
Abstract (en)
A combination therapy for treating PIK3CA-mutated cancer, comprising administering a PI3K inhibitor, a prostaglandin receptor (PGE2) inhibitor, and a PD-1 inhibitor to a subject in need thereof. The anti-tumor activity brought about by a three-drug combination method is significantly superior to that brought about by a two-drug combination method of the PI3K inhibitor and the PD-1 inhibitor, and the prostaglandin receptor (PGE2) and the PD-1 inhibitor.
IPC 8 full level
A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP KR)
A61K 31/415 (2013.01 - EP); A61K 31/4152 (2013.01 - KR); A61K 31/5377 (2013.01 - EP KR); A61K 39/395 (2013.01 - KR); A61K 45/06 (2013.01 - EP KR); A61P 35/00 (2018.01 - EP KR); A61K 39/39558 (2013.01 - EP); A61K 2039/505 (2013.01 - KR); A61K 2300/00 (2013.01 - KR); C07K 16/2818 (2013.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
EP 4252774 A1 20231004; CN 116635074 A 20230822; JP 2023551046 A 20231206; KR 20230113594 A 20230731; TW 202227089 A 20220716; WO 2022111714 A1 20220602
DOCDB simple family (application)
EP 21897214 A 20211130; CN 2021134189 W 20211130; CN 202180080182 A 20211130; JP 2023532591 A 20211130; KR 20237021709 A 20211130; TW 110144459 A 20211129